🧠 This Week in Neuroscience: Sanofi-Vigil Neuroscience Deal, iPSC Milestones, Redosable Gene Therapy & More!
In this week’s Neuroscience Updates, we spotlight groundbreaking advances driving the future of neurodegeneration, cell therapy, and migraine innovation.
✨ Key updates include:
💊 Sanofi acquires Vigil Neuroscience for $470M to advance VG-3927, a TREM2-targeting Alzheimer’s candidate
🧬 BioArctic’s Exidavnemab earns EU orphan drug designation for multiple system atrophy (MSA)
💪 CureDuchenne invests $1M in Entos’ Fusogenix platform for redosable full-length dystrophin gene therapy
🧠 UniXell doses first patient in China using iPSC-derived cell therapy for Parkinson’s disease
♿ China approves world’s first allogeneic iPSC therapy for spinal cord injury, led by Sun Yat-sen University
🤕 Salvia BioElectronics raises €53M Series B to launch MySalvia Therapy, a thin implant for chronic migraine
Whether you’re in clinical research, biotech strategy, or neurotherapeutics development—this update delivers the critical insights you need to stay ahead in brain health innovation.
📢 Stay Ahead in Neuroscience Research!
✅ Like, share, and subscribe for weekly updates on neuroscience, neurodegeneration, and clinical trials
#NeuroscienceNews #AlzheimersTreatment #MSA #GeneTherapy #iPSCTherapy #ParkinsonsDisease #SpinalCordInjury #MigraineRelief #ClinicalTrials #HealthcareInnovation #LucidQuest #BiotechNews #BrainHealth #NeuroUpdates #OrphanDrugDesignation